These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16310293)

  • 1. Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection.
    Antonis AF; Claassen EA; Hensen EJ; de Groot RJ; de Groot-Mijnes JD; Schrijver RS; van der Most RG
    Vaccine; 2006 Mar; 24(10):1551-61. PubMed ID: 16310293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus.
    Mapletoft JW; Oumouna M; Townsend HG; Gomis S; Babiuk LA; van Drunen Littel-van den Hurk S
    Virology; 2006 Sep; 353(2):316-23. PubMed ID: 16828832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
    Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated bovine respiratory syncytial virus prior to challenge.
    Woolums AR; Gunther RA; McArthur-Vaughan K; Anderson ML; Omlor A; Boyle GA; Friebertshauser KE; McInturff PS; Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2004 Jan; 27(1):57-74. PubMed ID: 14656542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
    Ellis J; Gow S; West K; Waldner C; Rhodes C; Mutwiri G; Rosenberg H
    J Am Vet Med Assoc; 2007 Jan; 230(2):233-43. PubMed ID: 17223757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.
    Oumouna M; Mapletoft JW; Karvonen BC; Babiuk LA; van Drunen Littel-van den Hurk S
    J Virol; 2005 Feb; 79(4):2024-32. PubMed ID: 15681404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves.
    Kalina WV; Woolums AR; Gershwin LJ
    Vaccine; 2005 Aug; 23(37):4625-30. PubMed ID: 15967545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dual vaccination for bovine respiratory syncytial virus and Haemophilus somnus on immune responses.
    Berghaus LJ; Corbeil LB; Berghaus RD; Kalina WV; Kimball RA; Gershwin LJ
    Vaccine; 2006 Aug; 24(33-34):6018-27. PubMed ID: 16777273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of antigen-specific T-cell subset activation to bovine respiratory disease viruses by a modified-live virus vaccine.
    Platt R; Burdett W; Roth JA
    Am J Vet Res; 2006 Jul; 67(7):1179-84. PubMed ID: 16817740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine responses of bovine dendritic cells and T cells following exposure to live or inactivated bovine respiratory syncytial virus.
    Werling D; Collins RA; Taylor G; Howard CJ
    J Leukoc Biol; 2002 Aug; 72(2):297-304. PubMed ID: 12149420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine respiratory syncytial virus-specific immune responses in calves after inoculation with commercially available vaccines.
    Ellis JA; Hassard LE; Morley PS
    J Am Vet Med Assoc; 1995 Feb; 206(3):354-61. PubMed ID: 7751246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves.
    Ellis JA; Hassard LE; Cortese VS; Morley PS
    J Am Vet Med Assoc; 1996 Feb; 208(3):393-400. PubMed ID: 8575972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternaria aerosol during a bovine respiratory syncytial virus infection alters the severity of subsequent re-infection and enhances IgE production.
    Kalina WV; Anderson ML; Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2006; 29(2-3):138-56. PubMed ID: 16644011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunology of bovine respiratory syncytial virus infection of cattle.
    Gershwin LJ
    Comp Immunol Microbiol Infect Dis; 2012 May; 35(3):253-7. PubMed ID: 22410266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to experimentally induced infection with bovine respiratory syncytial virus following intranasal vaccination of seropositive and seronegative calves.
    Ellis JA; Gow SP; Goji N
    J Am Vet Med Assoc; 2010 May; 236(9):991-9. PubMed ID: 20433400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunobiology of bovine respiratory syncytial virus infections].
    Schrijver RS
    Tijdschr Diergeneeskd; 1998 Nov; 123(22):658-62. PubMed ID: 9836385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccination against pseudorabies virus and bovine respiratory syncytial virus infections of young animals in the face of maternally derived immunity.
    Hamers C; Juillard V; Fischer L
    J Comp Pathol; 2007 Jul; 137 Suppl 1():S35-41. PubMed ID: 17553517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.